Atypical antipsychotic use in patients with dementia: Managing safety concerns

American Journal of Psychiatry

Volumn 169, Issue 9, 2012, Pages 900-906

  Steinberg, Martin ^a   Lyketsos, Constantine G ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; ZIPRASIDONE;

ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; CLINICAL DECISION MAKING; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISTRESS SYNDROME; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ELDERLY CARE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FALLING; FEMUR FRACTURE; FRACTURE; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HIP FRACTURE; HUMAN; HYPERGLYCEMIA; METABOLIC DISORDER; MORTALITY; ORTHOSTATIC HYPERTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SAFETY; PATIENT SELECTION; PNEUMONIA; POLYPHARMACY; PRIORITY JOURNAL; PULMONARY ASPIRATION; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEDATION; SIDE EFFECT; STROKE; TARDIVE DYSKINESIA; WEIGHT GAIN; XEROSTOMIA;

EID: 84865835392     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12030342     Document Type: Review

References (52)

1. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot P, Yaffe K: ANCP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008; 33:957-970 (Pubitemid 351367549)
2. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, Breitner JCS, Steffens DC, Tschanz JT; Cache County Investigators: Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008; 23:170-177 (Pubitemid 351308497)
3. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934-1943 (Pubitemid 41464695)
4. Trifirò G, Spina E, Gambassi G: Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 2009; 59:1-12
5. US Food and Drug Administration: Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. April 11, 2004. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171. htm
6. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210
7. American Geriatrics Society 2012 Beers Criteria Update Expert Panel: American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2012; 60:616-631
8. Gurwitz JH, Field TS, Judge J, Rochon P, Harrold LR, Cadoret C, Lee M, White K, LaPrino J, Erramuspe-Mainard J, DeFlorio M, Gavendo L, Auger J, Bates DW: The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118:251-258 (Pubitemid 40312636)
9. Rochon PA, Normand SL, Gomes T, Gill SS, Anderson GM, Melo M, Sykora K, Lipscombe L, Bell CM, Gurwitz JH: Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008; 168:1090-1096 (Pubitemid 351749226)
10. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M; Risperidone Study Group: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60:107-115 (Pubitemid 29104387)
11. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A; HGEU Study Group: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000; 57:968-976
12. Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH: A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 2008; 16:537-550
13. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525-1538 (Pubitemid 44547805)
14. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS; CATIE-AD Study Group: Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165:844-854 (Pubitemid 351948716)
15. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293:596-608 (Pubitemid 40171242)
16. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC: Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169:71-79
17. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG: Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009; 5:245-255
18. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, Blow FC: Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007; 164:1568-1576 (Pubitemid 350069737)
19. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, Gurwitz JH, Rochon PA: Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146:775-786 (Pubitemid 351650498)
20. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R; DART-AD investigators: The Dementia Antipsychotic Withdrawal Trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8:151-157
21. Trifirò G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC: All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf 2007; 16:538-544 (Pubitemid 46824275)
22. Liperoti R, Onder G, Landi F, Lapane KL, Mor V, Bernabei R, Gambassi G: All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 2009; 70:1340-1347
23. Musicco M, Palmer K, Russo A, Caltagirone C, Adorni F, Pettenati C, Bisanti L: Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease. Dement Geriatr Cogn Disord 2011; 31:218-224
24. Risperdal (risperidone) "Dear Healthcare Professional" letter, April 2003. www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm168933.htm
25. Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, Knol W, Heerdink ER: Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol 2009; 23:909-914
26. Herrmann N, Lanctôt KL: Do atypical antipsychotics cause stroke? CNS Drugs 2005; 19:91-103 (Pubitemid 40321762)
27. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, Bernabei R: Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66:1090-1096 (Pubitemid 41442273)
28. Simon V, van Winkel R, De Hert M: Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009; 70:1041-1050
29. Albert SG, Grossberg GT, Thaipisuttikul PJ, Scouby J, Green E: Atypical antipsychotics and the risk of diabetes in an elderly population in long-term care: a retrospective nursing home chart review study. J Am Med Dir Assoc 2009; 10:115-119
30. Rondanelli M, Sarra S, Antoniello N, Mansi V, Govoni S, Falvo F, Solerte SB, Ferrari E: No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease. Minerva Med 2006; 97:147-151 (Pubitemid 43966273)
31. Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Stroup TS, Sultzer DL, Tariot PN, Vigen C, Schneider LS: Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry 2009; 166:583-590
32. Weiden PJ: EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007; 13:13-24
33. Kurlan R, Cummings J, Raman R, Thal L; Alzheimer's Disease Cooperative Study Group: Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68:1356-1363 (Pubitemid 46659086)
34. Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, Normand SL, Mamdani M, Lee PE, Li P, Bronskill SE, Marras C, Gurwitz JH: Atypical antipsychotics and parkinsonism. Arch Intern Med 2005; 165:1882-1888 (Pubitemid 41352083)
35. Jeste DV: Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004; 65(suppl 9):21-24
36. Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, Shulman KI, Stukel T, Normand SL, Rochon PA: Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005; 53:1374-1379 (Pubitemid 41602483)
37. Hartikainen S, Lönnroos E, Louhivuori K: Medication as a risk factor for falls: critical systematic review. J Gerentol A Biol Sci Med Sci 2007; 62:1172-1181 (Pubitemid 47599431)
38. Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD: Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 2008; 28:384-391
39. Liperoti R, Onder G, Lapane KL, Mor V, Friedman JH, Bernabei R, Gambassi G: Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry 2007; 68:929-934 (Pubitemid 47015494)
40. Pratt N, Roughead EE, Ramsay E, Salter A, Ryan P: Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Saf 2011; 34:567-575
41. Jalbert JJ, Eaton CB, Miller SC, Lapane KL: Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc 2010; 11:120-127
42. Dore DD, Trivedi AN, Mor V, Friedman JH, Lapane KL: Atypical antipsychotic use and risk of fracture in persons with parkinsonism. Mov Disord 2009; 24:1941-1948
43. Caballero J, Hitchcock M, Scharre D, Beversdorf D, Nahata MC: Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Clin Ther 2006; 28:1695-1700 (Pubitemid 44838896)
44. Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS: Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 2011; 168:831-839
45. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330:874
46. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, Bernabei R: Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med 2005; 165:696-701 (Pubitemid 40393155)
47. Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC: Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008; 56:661-666 (Pubitemid 351473519)
48. Teri L, Logsdon RG: Assessment and management of behavioral disturbances in Alzheimer disease. Compr Ther 2000; 26:169-175
49. Cohen-Mansfield J: Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001; 9:361-381
50. Rabins PV, Lyketsos CG: Antipsychotic drugs in dementia: what should be made of the risks? JAMA 2005; 294:1963-1965 (Pubitemid 41464699)
51. Meeks TW, Jeste DV: Beyond the black box: what is the role for antipsychotics in dementia? Curr Psychiatry 2008; 7:50-65
52. Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, Kossakowski K, Yu LM, Juszczak E; Investigators DART AD: A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DARTAD trial). PLoS Med 2008; 59:e76